ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $600,000 | -28.9% | 29,905 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $844,000 | +64.2% | 29,905 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $514,000 | -15.3% | 29,905 | -0.9% | 0.00% | 0.0% |
| Q4 2022 | $607,000 | -6.3% | 30,174 | +0.8% | 0.00% | -50.0% |
| Q3 2022 | $648,000 | -23.6% | 29,927 | -1.0% | 0.00% | 0.0% |
| Q2 2022 | $848,000 | -39.3% | 30,218 | -0.1% | 0.00% | -33.3% |
| Q1 2022 | $1,396,000 | -45.1% | 30,243 | -0.1% | 0.00% | -50.0% |
| Q4 2021 | $2,544,000 | +27.6% | 30,262 | +1.2% | 0.01% | +20.0% |
| Q3 2021 | $1,993,000 | +25.3% | 29,905 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $1,591,000 | – | 29,905 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |